Cellular immunotherapy for acute myeloid leukemia using dendritic cells pulsed with WT1 peptide and zoledronate

Trial Profile

Cellular immunotherapy for acute myeloid leukemia using dendritic cells pulsed with WT1 peptide and zoledronate

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2009

At a glance

  • Drugs WT1 peptide-loaded dendritic cell vaccine; WT1 peptide-loaded dendritic cell vaccine; Zoledronic acid; Zoledronic acid
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2009 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 08 Jun 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top